Oral cyclosphorin formulations

Details Oral cyclosphorin formulations Oral cyclosphorin formulations

1998-03-09

2001-07-03

Webman, Edward J. (Department: 1617)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Capsules

C514S885000, C514S962000, C514S975000

Reexamination Certificate

active

06254885

ABSTRACT:

INTRODUCTION
1. Field of the Invention
The field of this invention is oral cyclosporin formulations.
2. Background
Despite efforts to avoid graft rejection through host-donor tissue type matching, in the majority of transplantation procedures where a donor organ is introduced into a host, immunosuppressive therapy is critical to the maintained viability of the donor organ in the host. A variety of immunosuppressive agents have been employed in transplantation procedures, including azathioprine, methotrexate, cyclophosphamide, FK-506, rapamycin and corticosteroids. Agents finding increased use in immunosuppressive therapy due to their preferential effect on T-cell mediated reactions are the cyclosporins.
Cyclosporins are a class of cyclic polypeptides consisting of eleven amino acids which are produced as a metabolite by the fungus species Tolypocladium inflatum Gams. Cyclosporins have been observed to reversibly inhibit immunocompetent lymphocytes, particularly T-lymphocytes, in the G
0
or G
1
phase of the cell cycle. Cyclosporins have also been observed to reversibly inhibit lymphokine production and release. Although a number of cyclosporins are known, Cyclosporin A is the most widely used.
Use of Cyclosporin A has been reported to prolong the survival of allogeneic transplants involving skin, heart, kidney, pancreas, bone marrow, small intestine and lung. In allogeneic transplantations, Cyclosporin A has been shown to suppress humoral immunity and, to a greater extent, cell mediated immune reactions, including: allograft rejection, delayed hypersensitivity, experimental allergic encephalomyelitis, Freund's adjuvant arthritis, and graft vs. host disease. Although success has been realized with Cyclosporin A, following transplantation administration of the agent must be continued since the benefits of cyclosporin therapy are reversible and graft rejection occurs once administration of Cyclosporin A is discontinued.
Although cyclosporin formulations for both oral and intravenous administration have been developed, oral administration of cyclosporin is preferred because of the ease of administration and greater patient acceptance. Furthermore, intravenous administration of cyclosporin can result in anaphylactic reactions, a side effect not observed with oral formulations. Oral cyclosporin formulations which have been developed and are currently marketed include both soft gelatin capsule and solution formulations, both of which are sold under the trademarks SANDIMMUNE® and NEORALS™.
In using oral cyclosporin formulations in immunosuppressive therapy, both the care giver and manufacturer must be cognizant of many issues. With oral cyclosporin formulations, cydosporin bioavailablity can be limited because of cyclosporin's immiscibility in water and the tendency of cyclosporin to precipitate in aqueous environments. In addition, the concentration of cyclosporin present in oral formulations can be limited due to cyclosporin's hydrophobic nature. Furthermore, cyclosporin absorption by the gastrointestinal tract can be erratic from one formulation batch to the next, requiring constant monitoring of cyclosporin blood levels during treatment. Finally, packaging and storage stability are an issue with oral formulations. For example, with soft gelatin capsule formulations of cyclosporin, air tight packaging must be employed, which is inconvenient due to bulkiness and high cost. Furthermore, cyclosporine formulations may be unstable at lower temperatures, as cyclosporine crystalization may occur.
Thus, desirable oral cyclosporin formulations would be formulations that address at least some of the above issues. Ideally, oral formulations would promote high bioavailability, comprise high concentrations of cyclosporin and would be amenable to preparation in hard capsule form.
Relevant Literature
Physician's Desk Reference (1994) pp 2071-2074 describes oral cyclosporin formulations curly sold under the trademark SANDIMMUNE®.
Oral cyclosporine formulations are also described in the NEORAL™ package insert, (1995) (Sandoz Pharmaceuticals Corporation, East Hanover, N.J., 07936).
U.S. Patents of interest describing cyclosporins and derivatives thereof include: 4,220,641; 4,639,434; 4,289,851; and 4,384,996. U.S. Pat. No. 5,047,396 describes an intravenous preparation for administration of cyclosporin. U.S. Pat. Nos. 4,388,307; 4,970,076 and 4,990,337 describe the preparation of oral cyclosporin formulations.
The preparation of hard capsules for the oral delivery of pharmaceutical formulations is described in U.S. Pat. Nos. 4,822,618; 4,576,284; 5,120,710; and 4,894,235.
BRIEF SUMMARY OF THE INVENTION
Oral cyclosporin formulations, and methods for their use in immunosuppressive therapy, are provided. In the subject formulations, cyclosporin is present in an orally acceptable vehicle comprising at least one alkanol solvent of from 2 to 3 carbon atoms in combination with at least one non-ionic surfactant. The subject formulations may further comprise one or more cosolvents, where cosolvents of interest are fatty acid esters and diols. The cyclosporin formulations can be packaged as hard capsules.


REFERENCES:
patent: 506219 (1893-04-01), Desai
patent: 4117118 (1978-09-01), Harri et al.
patent: 4220641 (1980-09-01), Traber et al.
patent: 4329332 (1982-05-01), Couvreur et al.
patent: 4388307 (1983-06-01), Cavanak
patent: 4489055 (1984-12-01), Couvreur et al.
patent: 4501726 (1985-02-01), Schröder et al.
patent: 4780316 (1988-10-01), Brox
patent: 4792449 (1988-12-01), Ausman et al.
patent: 4889723 (1989-12-01), Kim et al.
patent: 4945121 (1990-07-01), Micale et al.
patent: 4970076 (1990-11-01), Horrobin
patent: 4990337 (1991-02-01), Kurihara et al.
patent: 4996193 (1991-02-01), Hewitt et al.
patent: 5047396 (1991-09-01), Orban et al.
patent: 5051402 (1991-09-01), Kurihara et al.
patent: 5118493 (1992-06-01), Kelley et al.
patent: 5118528 (1992-06-01), Fessi et al.
patent: 5122383 (1992-06-01), Heiber et al.
patent: 5133908 (1992-07-01), Stainmesse et al.
patent: 5154930 (1992-10-01), Popescu et al.
patent: 5302401 (1994-04-01), Liversidge et al.
patent: 5326552 (1994-07-01), Na et al.
patent: 5342625 (1994-08-01), Hauer et al.
patent: 5350741 (1994-09-01), Takada
patent: 5352459 (1994-10-01), Hollister et al.
patent: 5364632 (1994-11-01), Benita et al.
patent: 5389382 (1995-02-01), List et al.
patent: 5393791 (1995-02-01), Roberts
patent: 5407609 (1995-04-01), Tice et al.
patent: 5429824 (1995-07-01), June
patent: 5430017 (1995-07-01), Antalne et al.
patent: 5472749 (1995-12-01), Dravid et al.
patent: 5504068 (1996-04-01), Komiya et al.
patent: 5518738 (1996-05-01), Eickhoff et al.
patent: 5543158 (1996-08-01), Gref et al.
patent: 5543393 (1996-08-01), Kim et al.
patent: 5565188 (1996-10-01), Wong et al.
patent: 5573783 (1996-11-01), Desieno et al.
patent: 5585020 (1996-12-01), Becker et al.
patent: 5587143 (1996-12-01), Wong et al.
patent: 5589455 (1996-12-01), Woo
patent: 5614219 (1997-03-01), Wunderlich et al.
patent: 5614491 (1997-03-01), Walch et al.
patent: 5620708 (1997-04-01), Amkraut et al.
patent: 5629021 (1997-05-01), Wright
patent: 5641515 (1997-06-01), Ramtoola et al.
patent: 5665277 (1997-09-01), Johnson et al.
patent: 5665331 (1997-09-01), Bagchi et al.
patent: 5674531 (1997-10-01), Ahlers et al.
patent: 5683723 (1997-11-01), Spenlehauer et al.
patent: 5702727 (1997-12-01), Amkraut et al.
patent: 5705194 (1998-01-01), Wong et al.
patent: 5705196 (1998-01-01), Valdivia et al.
patent: 5716642 (1998-02-01), Bagchi et al.
patent: 5717030 (1998-02-01), Dunn et al.
patent: 5733925 (1998-03-01), Kuntz et al.
patent: 5744153 (1998-04-01), Yewey et al.
patent: 5766635 (1998-06-01), Spenleuhauer et al.
patent: 5780044 (1998-07-01), Yewey et al.
patent: 5811447 (1998-09-01), Kuntz et al.
patent: 5833647 (1998-11-01), Edwards
patent: 5843509 (1998-12-01), Salve et al.
patent: 2009533 (1990-09-01), None
patent: 1326995 (1994-02-01), None
patent: 2106827 (1994-03-01), None
patent: 43 40 781 (1995-06-01), None
patent: 195 39 860 (1996-05-01), None
patent: 0 572 942 A2 (1993-1

Affiliated with

Also associated with

Rating

Oral cyclosphorin formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oral cyclosphorin formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral cyclosphorin formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2521587